Phase 3 Study Shows Statistically Significant Survival With Tebentafusp in Metastatic Uveal MelanomaDecember 15, 2020 • By Support
Source: Targeted Oncology, November 2020
Overall survival (OS) was statistically significantly improved with tebentafusp compared with investigator’s choice of therapy as treatment of patients with metastatic uveal melanoma in the phase 3 IMCgp100-202 study (NCT03070392), Immunocore announced in a press release.
The novel bispecific protein is made of a soluble T-cell receptor that is fused to an anti-CD3 immune-effector function, and it targets gp100 specifically, an antigen expressed in melanocytes and melanoma.
Tebentafusp is the first agent coming out of the ImmTAC technology platform at Immunocore that is designed to redirect and activate T-cells to identify and kill tumor cells.
[button link="https://www.targetedonc.com/view/phase-3-study-shows-statistically-significant-survival-with-tebentafusp-in-metastatic-uveal-melanoma" window="yes"]READ THE ORIGINAL FULL ARTICLE[/button]